MA53135B1 - C-mannoside compounds useful for the treatment of urinary tract infections - Google Patents

C-mannoside compounds useful for the treatment of urinary tract infections

Info

Publication number
MA53135B1
MA53135B1 MA53135A MA53135A MA53135B1 MA 53135 B1 MA53135 B1 MA 53135B1 MA 53135 A MA53135 A MA 53135A MA 53135 A MA53135 A MA 53135A MA 53135 B1 MA53135 B1 MA 53135B1
Authority
MA
Morocco
Prior art keywords
treatment
urinary tract
compounds useful
tract infections
mannoside compounds
Prior art date
Application number
MA53135A
Other languages
French (fr)
Other versions
MA53135A (en
Inventor
Katherine Louisa Widdowson
Eugene L Stewart
Michael Joseph Bishop
Vincent J Colandrea
Yuehu Li
Iulia Strambeanu
James Walter Janetka
Laurel Kathryn Mcgrane
Original Assignee
Glaxosmithkline Ip Dev Ltd
Fimbrion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Fimbrion Therapeutics Inc filed Critical Glaxosmithkline Ip Dev Ltd
Priority claimed from PCT/IB2019/055806 external-priority patent/WO2020012336A1/en
Publication of MA53135A publication Critical patent/MA53135A/en
Publication of MA53135B1 publication Critical patent/MA53135B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés et compositions de c-mannoside et leur application en tant que produits pharmaceutiques pour le traitement d'une maladie humaine. L'invention concerne également des procédés d'inhibition de l'activité fimh chez un sujet humain pour le traitement de maladies telles qu'une infection des voies urinaires.The invention relates to novel c-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. The invention also relates to methods of inhibiting fimh activity in a human subject for the treatment of diseases such as a urinary tract infection.

MA53135A 2018-07-10 2019-07-08 C-mannoside compounds useful for the treatment of urinary tract infections MA53135B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862695993P 2018-07-10 2018-07-10
PCT/IB2019/055806 WO2020012336A1 (en) 2018-07-10 2019-07-08 C-mannoside compounds useful for the treatment of urinary tract infections

Publications (2)

Publication Number Publication Date
MA53135A MA53135A (en) 2021-05-19
MA53135B1 true MA53135B1 (en) 2022-11-30

Family

ID=74672507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53135A MA53135B1 (en) 2018-07-10 2019-07-08 C-mannoside compounds useful for the treatment of urinary tract infections

Country Status (2)

Country Link
AR (1) AR115709A1 (en)
MA (1) MA53135B1 (en)

Also Published As

Publication number Publication date
AR115709A1 (en) 2021-02-17
MA53135A (en) 2021-05-19

Similar Documents

Publication Publication Date Title
MA47079B1 (en) Amino-triazolopyidin compounds and their use to treat cancer
MA33295B1 (en) NEW FORMULATION OF DICLOFENAC
ATE396973T1 (en) BENZYL ETHER AND BENZYLAMINO BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ES2168471T3 (en) 2- (5H) -FURANONAS DIARIL-5-OXIGENADAS AS INHIBITORS OF THE COX-2.
TN2009000138A1 (en) Biaryl-ETHER-UREA
MA33467B1 (en) Primary drugs include insulin-linking facilities
MA33419B1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
ATE538651T1 (en) SPIROPIPERIDINE INHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MA35513B1 (en) Pharmaceutical compositions comprising 40 - o - (2 - hydroxy) ethyl - rapamycin
CR20240003A (en) Novel therapeutic delivery moieties and uses thereof
MA56019A (en) NEW COMPOUNDS AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
MA40955B1 (en) 2-amino-6- (difluoromethyl) -5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MA32798B1 (en) Naftilacetic acids
UY28279A1 (en) FENACILO 2 -HIDROXI - 3 - DIAMINOALCANOS
EA200802020A1 (en) TETRAHYDROPYRIMIDAOZEPINA AND THEIR APPLICATION AS TRPV 1 MODULATORS
MA35411B1 (en) New therapeutic composition containing apomorphine as active ingredient
MA32108B1 (en) Indendazole derivatives
ATE448785T1 (en) TREATMENT OF INFLAMMATORY BOWEL DISEASE
MA30720B1 (en) ANALOGUES OF 2-PHENOXYPYRIMIDINONE
RU2018124487A (en) Treatment of intrahepatic cholestasis and related liver diseases
MX2021000340A (en) C-mannoside compounds useful for the treatment of urinary tract infections.
MA63848A1 (en) METHODS OF TREATMENT OF SPLENOMEGALY
ATE399758T1 (en) DERIVATIVES OF 1-PHENYLALKANECARBONIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
MA53135B1 (en) C-mannoside compounds useful for the treatment of urinary tract infections
EA202193190A1 (en) COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS